![]() |
|
|
Vol. 304, Issue 1, 342-348, January 2003
Departamento de Bioquimica (J.P., T.P., S.M.) and Departamento de Óptica (A.P.), Escuela Universitaria de Óptica, Universidad Complutense de Madrid, Madrid, Spain; and Department of Anatomy and Developmental Biology (C.H.V.H.), University College London, London, United Kingdom
| |
Abstract |
|---|
|
|
|---|
Adenine dinucleotides are present in many biological systems and may
serve as physiological regulators of processes such as neurotransmitter
release, vascular tone or corneal hydration. The presence of
diadenosine polyphosphates was investigated in New Zealand White rabbit
aqueous humor. Diadenosine tetraphosphate (Ap4A) and
diadenosine pentaphosphate (Ap5A) were identified and quantified in the aqueous humor with concentrations of 0.34 ± 0.1 and 0.08 ± 0.01 µM, respectively. The effects of topical
corneal application of diadenosine pyrophosphate (Ap2A),
diadenosine triphosphate (Ap3A), Ap4A, and
Ap5A on intraocular pressure in rabbits were also studied.
Ap2A, Ap3A, and Ap5A increased
intraocular pressure with threshold doses of approximately 0.1 to 1.0 µg · 10 µl
1. Ap4A decreased
intraocular pressure with an IC50 value of 0.12 µg
· 10 µl
1 (or 0.13 nmol). Cross-desensitization
studies suggested the activation of a P2X receptor for the hypotensive
effect of Ap4A and a P2Y receptor in the case of
Ap5A. The ATP receptor antagonists (all 100 µg · 10 µl
1), pyridoxal
phosphate-6-azophenyl-2',4'-disulfonic acid (PPADS), suramin, and
reactive blue 2 (RB-2) alone had no effect on intraocular pressure but
attenuated responses to diadenosine polyphosphates by approximately
80%. It is concluded that Ap2A, Ap3A, and
Ap5A increase intraocular pressure, and Ap4A
decreases intraocular pressure via mechanisms that involve P2
receptors, and that Ap4A present in aqueous humor may serve
to regulate intraocular pressure. Furthermore, we suggest that topical
application of Ap4A to the cornea has therapeutic potential
for lowering intraocular pressure, a major risk factor for glaucoma.
| |
Introduction |
|---|
|
|
|---|
Diadenosine
polyphosphates (abbreviated to ApnA, where
n = 2-7) are natural compounds. In particular
diadenosine triphosphate (Ap3A), diadenosine
tetraphosphate (Ap4A), diadenosine pentaphosphate
(Ap5A), Ap6A, and
Ap7A are found in exocytotic vesicles, such as
those in nerve terminals, adrenal medullary chromaffin cells, and
platelets (Flodgaard and Klenow, 1982
; Rodriguez del Castillo et al.,
1988
; Pintor et al., 1992a
,b
,c
, 1997
; Schlütter et al., 1994
;
Pintor and Miras-Portugal, 1995
; Jankowski et al., 1999
), and
diadenosine pyrophosphate (Ap2A) has recently
been identified in secretory granules of cardiac myocytes (Luo et al., 1999
). They have diverse actions in peripheral and central tissues because of their roles as extracellular signal molecules (Hoyle, 1990
;
Pintor et al., 1996
; Kisselev et al., 1998
; Hoyle et al., 2001
).
Ap4A and Ap5A have been
found in rabbit tears (Pintor et al., 2002b
), and both of these
dinucleotides together with Ap3A have been
isolated from human tears (Pintor et al., 2002a
,b
). In rabbits, topical corneal application of Ap4A or
Ap5A, but not Ap2A or
Ap3A, evokes tear secretion (Pintor et al.,
2002a
,b
), suggesting that these two dinucleotides play a role in the
regulation of corneal hydration and cleaning.
The mechanisms that control and regulate intraocular pressure are not
fully understood, but it results from the dynamic equilibrium between
the production and drainage (or resorption) of aqueous humor. In
general terms, sympathetic activity results in a reduction in
intraocular pressure, and parasympathetic activity results in an
increase. It seems that the main point of control of intraocular pressure is the outflow of aqueous humor, rather than its production (Burke and Potter, 1986
; Judge and Flitcroft, 2000
; Jumblatt, 2000
).
Intraocular pressure may also be regulated by effectors of circadian
rhythms, and we have recently shown that melatonin and the
MT3 receptor ligand,
5-methoxycarbonylamino-N-acetyltryptamine (5-MCA-NAT or GR
135531), can cause profound decreases in pressure (Pintor et al.,
2001
).
In the present experimental work, we describe the presence of diadenosine polyphosphates in the aqueous humor and the differential effects of a series of diadenosine polyphosphates, Ap2A, Ap3A, Ap4A, and Ap5A, which includes those known to be present in tears, on intraocular pressure in the rabbit. Our results suggest that one of them, Ap4A, has the potential to be used a therapeutic agent in conditions where intraocular pressure is elevated.
| |
Materials and Methods |
|---|
|
|
|---|
Animals. New Zealand White rabbits (males, 2-3 kg) were used. The animals were kept in individual cages with free access to food and water, under controlled 12-h light/dark cycles. Experiments were carried out in accordance with the European Communities Council Directive (86/609/EEC) and the Association for Research in Vision and Ophthalmology statement for the Use of Animals in Ophthalmic and Vision Research.
Aqueous Humor Collection and Sample Preparation.
New Zealand
White rabbits were anesthetized with 1.5 mg·kg
1 propofol (Abbott Laboratories, Madrid,
Spain). Aqueous humor was removed with a syringe connected to a
30-gauge needle in the sclero-corneal limbus area. Samples were stored
at
35°C before treatment. The treatment consisted of their
chromatography through a SEP-PAK Accell QMA cartridges (Waters,
Milford, MA) and elution of the retained nucleotides and dinucleotides
by means of a mixture of 0.1 N HCL 0.2 N KCl. Eluates were neutralized
with 10 N KOH before HPLC injection (Rotllán et al., 1991
).
HPLC Procedures. The HPLC system consisted of a Waters 1515 isocratic HPLC pump, a 2487 dual absorbance detector and a Reodyne injector, all managed by the software Breeze from Waters. The column was a Novapak C-18 (15 cm length, 0.4 cm diameter) from Waters.
The system was equilibrated overnight with the following mobile phase: 10 mM KH2PO4, 2 mM tetrabutyl ammonium, 17% acetonitrile, pH 7.5. Detection was monitored at 260 nm wavelength. All the peaks identified as putative diadenosine polyphosphates were taken for phosphodiesterase treatment. Phosphodiesterase (EC 3.1.15.1) from Crotalus durissus from Sigma-Aldrich (St. Louis, MO) at a concentration of 0.3 U/ml was incubated for 10 min with the corresponding putative dinucleotide and the digestion products were analyzed by HPLC.Intraocular Pressure Measurements.
Intraocular pressure was
measured by means of a Tono-Pen XL contact tonometer (Mentor
Massachusetts Inc., Norwell, MA). This device has been shown to be the
tonometer of choice for measuring intraocular pressures within the
range of 3 to 30 mm Hg in rabbits (Abrams et al., 1996
). All
measurements fell within this diapason: the mean baseline value of
intraocular pressure was 17.0 ± 0.39 mm Hg (n = 112). A topical anesthetic [Colircusí Laboratorios Cusí, Madrid, Spain (0.1 mg · ml
1 tetracaine plus 0.4 mg · ml
1 oxybuprocaine in 0.9% saline, diluted 1:3
in 0.9% saline)] was applied (10 µl) to the cornea before each
measurement of intraocular pressure was made (Pintor et al., 2001
).
Diadenosine polyphosphates or saline was applied topically to the
cornea in volumes of 10 µl.
Drugs Used.
Diadenosine pyrophosphate sodium salt,
diadenosine triphosphate ammonium salt, diadenosine tetraphosphate
ammonium salt, and diadenosine pentaphosphate sodium salt,
,
-meATP, suramin, and RB-2 were all obtained from Sigma-Aldrich.
ATP
S was purchased from Roche Diagnostics (Mannheim,
Germany). Pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid, was
obtained from Sigma/RBI (Natick, MA). All the dinucleotides were
dissolved in sterile saline (0.9%), to produce stocks with concentrations in the range from 1 ng · ml
1 to 1 mg · ml
1. Suramin, RB-2, and PPADS were diluted to
produce a stock of 1 mg · ml
1.
Analysis of Data.
Numerical values are given as mean ± S.E.M. Means of two groups were compared using Student's t
test (unpaired, two-tailed, unless stated) with a 5% fiducial point of
significance. Means of three or more groups were compared using
analysis of variance and post hoc Tukey's tests, using
= 0.05.
| |
Results |
|---|
|
|
|---|
Presence of Diadenosine Polyphosphates in the Aqueous Humor.
The analysis of nucleotide and dinucleotide content in rabbit aqueous
humor indicated the presence of several peaks, two of which were
tentatively identified as Ap4A and
Ap5A, when compared to commercial standards (Fig.
1). To confirm the nature of the putative
dinucleotides, samples were enriched with commercial dinucleotides that
coeluted together with the peaks present in the samples (results not
shown). To fully confirm the existence of Ap4A
and Ap5A in the aqueous humor, peaks were
collected and submitted to phosphodiesterase treatment. This enzyme
cleaves the dinucleotide giving AMP plus another nucleotide that
depends on the length of the phosphate chain in the original
dinucleotide. When diadenosine tetraphosphate was submitted to this
treatment, it was possible to observe the presence of AMP and ATP (Fig.
2, upper traces);
Ap5A digestion with phosphodiesterase gave AMP and adenosine 5'-tetraphosphate (Ap4) as products
(Fig. 2, lower traces). This treatment therefore confirmed that the two
dinucleotide peaks present in the aqueous humor corresponded to
Ap4A and Ap5A. The
concentrations of these dinucleotides were then calculated by
comparison with samples of commercial external standards.
Ap4A and Ap5A were present
in the aqueous humor at concentrations of 0.34 ± 0.1 and
0.08 ± 0.01 µM, respectively (n = 8).
|
|
Effect of Diadenosine Polyphosphates on Intraocular Pressure.
Ap2A and Ap3A both caused a
dose-dependent increase in intraocular pressure (Figs.
3 and 4).
The threshold dose was between 0.1 and 1.0 µg · 10 µl
1. The dose-response relationships did not
appear to saturate, there being no peak or plateau in the dose-response
curves before the highest dose (300 µg · 10 µl
1). Ap5A also caused
increases in intraocular pressure. However, a dose-response
relationship was not clear. At doses below 10 µg · 10 µl
1 responses were extremely variable, with a
coefficient of variability greater than the value of the mean (data not
shown). At doses of 10, 100, and 300 µg · 10 µl
1, increases in pressure were clear, but
lacked dose dependence (Fig. 4)
|
|
1, and a maximum response at a dose of 10 to 100 µg · 10 µl
1 (Fig.
5). The highest dose caused a fall in
pressure of 29.6 ± 2.2% (n = 8). Because there
was a clear maximum it was possible to calculate an
IC50, which was 0.12 µg · 10 µl
1, with 95% confidence limits of 0.03 and
0.62 µg · 10 µl
1. This is equivalent
to an absolute concentration of 13 µmol · l
1 (3.2, 67.2) µmol · l
1 (mean with 95% confidence limits).
|
|
Cross-Desensitization and Antagonist Studies. To study the receptors that mediate the actions of the diadenosine polyphosphates, cross-desensitization experiments with nucleotides were performed.
Homologous desensitization with two consecutive maximal doses of Ap4A demonstrated the lack of effect of the second application, both at concentrations of 100 µg · 10 µl
1. The preapplication of the hypotensive
mononucleotide
,
-meATP (100 µg · 10 µl
1) (Pintor and Peral, 2001
S (100 µg · 10 µl
1), and
hypertensive mononucleotide (Pintor and Peral., 2001
S after the application of
Ap4A was significantly smaller than ATP
S
alone, indicating the presence of the hypotensive effect of
Ap4A (data not shown). These results are
suggesting that
,
-meATP and Ap4A share the
same receptor activation, which is consistent with a reduction in IOP.
|
1), it was possible
to observe that the homologous desensitization abolished the effect
expected for the second application. When
,
-meATP (100 µg
· 10 µl
1) was pretreated it was possible to
see a small but not statistically significant reduction in the
,
-meATP effect. The application of ATP
S (100 µg · 10 µl
1) abolished completely the effect of
Ap5A, suggesting the activation of the same P2
receptor (n = 8; Fig. 7B).
To demonstrate the involvement of P2 receptors on the effects produced
by Ap4A and Ap5A, three P2
antagonists were used: suramin, RB-2 and PPADS. Application of suramin,
RB-2, or PPADS (100 µg · 10 µl
1) had
no significant effect on intraocular pressure; 150 min after application of the antagonists the intraocular pressure had hardly changed from the control level of 16.8 ± 0.5 mm Hg
(n = 10) to 17.2 ± 1.1 mm Hg (no significant
difference, paired t test).
Of the three antagonists (all tested at 100 µg · 10 µl
1) only RB-2 was unable to reverse the
hypotensive effect of Ap4A, while both suramin
and PPADS could completely abolish Ap4A response (n = 8; Fig. 8A). In the
case of Ap5A, only PPADS antagonized the
hypertensive effect of this dinucleotide. Neither suramin nor RB-2 were
able to revert the effect of Ap5A
(n = 8; Fig. 8B). Following application of PPADS, the
responses to all four dinucleotides (100 µg · µl
1) were severely and significantly
attenuated (Fig. 9).
|
|
| |
Discussion |
|---|
|
|
|---|
These results show, for the first time, the presence of
diadenosine polyphosphates in the aqueous humor of that New Zealand White rabbits. Chromatographic analysis of these dinucleotides demonstrated that Ap4A and
Ap5A are present in the aqueous humor in the low
micromolar range. Adenine mononucleotides were also identified in the
aqueous humor, and they may also participate in the regulation of the
IOP as previously indicated (Pintor and Peral, 2001
).
Our results also show that topical application of diadenosine polyphosphates to the cornea can have profound effects on intraocular pressure in the rabbit. Ap2A, Ap3A, and Ap5A all produced increases in pressure, while Ap4A produced a decrease. Cross-desensitization studies and antagonism with suramin, PPADS, and RB-2 indicate that the polyphosphates were acting via P2 receptors, although the subtypes involved have not been fully characterized.
Ap4A was a potent agonist and produced a decrease
in intraocular pressure at concentrations 3 orders of magnitude below
those at which Ap2A, Ap3A,
or Ap5A produced an increase. The dose-response curve for Ap4A did not appear to inflect at the
highest concentrations tested points at which activation of the
excitatory receptor might be expected. At the lowest concentrations
tested, none of Ap2A, Ap3A,
and Ap5A produced a decrease in intraocular
pressure, which implies that in addition to there being two separate
populations of receptors, one mediating an increase and the other a
decrease in intraocular pressure, this latter receptor is specific for Ap4A. It is possible that
Ap4A also activates the excitatory receptor, but
in the mixed population the effects of activation of the receptor that
mediates a decrease in pressure predominated. In this sense, cross-desensitization studies suggest that Ap4A
acts through the same receptor as
,
-meATP (a P2X receptor), while
Ap5A acts to the same as ATP
S (a P2Y receptor)
(Pintor and Peral, 2001
). It has not been possible to identify the
molecular mechanisms that link these two receptors and the
physiological processes that control IOP.
Ap4A and Ap5A are also
present in rabbit tears (Pintor et al., 2002b
), and both stimulate tear
secretion in rabbits, as does Ap6A, while
Ap2A and Ap3A do not
(Pintor et al., 2002b
). Their presence in tears and aqueous humor and
their effects on both tear secretion and intraocular pressure suggests
that they are serving physiological roles in maintaining corneal
hydration and eye pressure. The endogenous tear concentration of
Ap4A is close to 3 µM (Pintor et al., 2002b
),
and this is within its range of activity for reducing intraocular
pressure when topically applied as a single 10-µl dose. The
IC50 concentration was equivalent to 13 µM. It
is important to point out that the concentrations of diadenosine
polyphosphates determined in the aqueous humor may reflect a more
physiological concentration than those that occur when the
dinucleotides are applied topically. Diadenosine polyphosphates may be
partially hydrolyzed when passing through the cornea before reaching
the aqueous humor, therefore the real IC50 values
for these compounds in the eye anterior chamber should be lower than
that apparently obtained.
It is unusual to find a tissue or organ in which members of the
homologous series of diadenosine polyphosphates, with a chain length
from two to five, have opposing actions. However, there are examples of
receptors that are selective or specific for one or members of this
group of compounds. For example, receptors that are activated by
Ap4A but not other diadenosine nucleosides have
been described in recombinant rat P2X2 receptors,
expressed in Xenopus laevis oocytes. This receptor is
activated by Ap4A, but not
Ap2A, Ap3A, or
Ap5A (Pintor et al., 1996
; Wildman et al., 1999
).
The MM39 cell line, derived from human tracheal gland epithelium, possesses a native receptor that is also sensitive to
Ap4A but not Ap3A or
Ap5A (Saleh et al., 1999
). The P2 receptor on rat mast cells (the P2Z receptor, which opens a membrane pore) is activated
by Ap4A, but not other dinucleotides. This is
because Ap4A can bear four negative charges, one
per phosphate group, whereas smaller dinucleotides cannot, and larger
dinucleotides do not because they chelate divalent cations (Tatham et
al., 1988
). In contrast receptors that are activated by
Ap2A, Ap3A, and
Ap5A but not Ap4A have not
been identified with any clarity.
P2X receptors in the guinea pig vas deferens and urinary bladder are
insensitive to Ap2A, and
Ap3A is only a weak agonist (Hoyle et al., 1995
).
Similarly at P2X receptors in the rat mesenteric arterial bed
Ap4A, Ap5A, and
Ap6A are all agonists, while
Ap2A and Ap3A are not
(Ralevic et al., 1995
). In contrast, Ap2A and Ap3A are both good agonists of P2Y receptors in
the guinea pig taenia coli and rat mesenteric arterial endothelial
cells (Hoyle et al., 1995
; Ralevic et al., 1995
; Hourani et al., 1998
),
and in ECV304 cells, a cell line derived from human umbilical
endothelial cells, there is a P2Y receptor that is sensitive to
Ap3A but not Ap4A,
Ap5A, or Ap6A (Conant et
al., 1998
).
In conclusion, diadenosine polyphosphates are present in the rabbit aqueous humor, moreover, intraocular pressure can be regulated by topical corneal application of adenine dinucleotides. Ap4A potently decreases intraocular pressure; Ap2A, Ap3A, and Ap5A increase intraocular pressure. The receptors involved remain to be characterized, but the one activated by Ap4A bears similarities to some previously described P2X receptors. The fact that these adenine dinucleotides modulate intraocular pressure leads to the suggestion that they may be useful compounds in the development of therapeutic agents. In particular, Ap4A, or a derivative, may be useful in the treatment of ocular disorders such as forms of glaucoma, in which a reduction of intraocular pressure would be beneficial.
| |
Acknowledgments |
|---|
We thank The British Council for partial support (C.H.V.H.). This work has been supported by a grant from Inspire Pharmaceuticals.
| |
Footnotes |
|---|
Accepted for publication September 6, 2002.
Received for publication July 9, 2002.
DOI: 10.1124/jpet.102.041368
Address correspondence to: Dr. Jesús Pintor, Departmento de Bioquímica y Biología Molecular IV, Escuela Universitaria de Óptica, C/Arcos de Jalón s/n, 28037 Madrid, Spain. E-mail: jpintor{at}vet.ucm.es
| |
Abbreviations |
|---|
Ap2A, diadenosine pyrophosphate;
Ap3A, diadenosine triphosphate;
Ap4A, diadenosine tetraphoshate;
Ap5A, diadenosine
pentaphosphate;
Ap4, adenosine 5'-tetraphosphate;
,
-meATP,
,
-methylene adenosine 5'-triphosphate;
ATP
S, adenosine 5'-O-(3-thiotriphosphate);
HPLC, high
performance liquid chromatography;
IOP, intraocular pressure;
PPADS, pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid;
RB-2, reactive
blue 2.
| |
References |
|---|
|
|
|---|
2 agonist (UK 14,304-18) in cats, rabbits and monkeys.
Curr Eye Res
5:
665-672[Medline].
-P1,P4-tetraphosphate are present and releasable, but metabolically inactive, in human platelets.
Biochem J
208:
737-742[Medline].
-P1,P2-diphosphate and diadenosine 5',5
-P1,P3-triphosphate in human myocardial tissue.
FASEB J
13:
695-705
-P1,P4-tetraphosphate, a fluorescent enzymatically active derivative of Ap4A.
FEBS Lett
280:
371-374[CrossRef][Medline].This article has been cited by other articles:
![]() |
G. Burnstock Physiology and Pathophysiology of Purinergic Neurotransmission Physiol Rev, April 1, 2007; 87(2): 659 - 797. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Burnstock Pathophysiology and therapeutic potential of purinergic signaling. Pharmacol. Rev., March 1, 2006; 58(1): 58 - 86. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Soto, J. Pintor, A. Peral, A. Gual, and X. Gasull Effects of Dinucleoside Polyphosphates on Trabecular Meshwork Cells and Aqueous Humor Outflow Facility J. Pharmacol. Exp. Ther., September 1, 2005; 314(3): 1042 - 1051. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. E. Crosson, P. W. Yates, A. N. Bhat, Y. V. Mukhin, and S. Husain Evidence for Multiple P2Y Receptors in Trabecular Meshwork Cells J. Pharmacol. Exp. Ther., May 1, 2004; 309(2): 484 - 489. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Pintor, T. Pelaez, and A. Peral Adenosine Tetraphosphate, Ap4, a Physiological Regulator of Intraocular Pressure in Normotensive Rabbit Eyes J. Pharmacol. Exp. Ther., February 1, 2004; 308(2): 468 - 473. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||